alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
"['V299L', 'F317L', 'G250E']","[{'ncitCode': 'C60809', 'drugName': 'Bosutinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],['26040495'],[],"Bosutinib is a dual SRC/ABL kinase inhibitor that is FDA-approved for adult patients with either newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) or CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy and is NCCN-listed for patients with relapsed/refractory Ph+ ALL. In a phase I/II trial (NCT00261846) of bosutinib in 24 patients with Ph+ ALL with resistance or intolerance to prior TKI therapy, 13/24 (54%) patients had mutation assessment at baseline, revealing mutations in F317L (n = 1) and G250E (n = 1) (PMID 26040495). Neither of these patients achieved an overall hematologic response (OHR) or a major cytogenetic response (MCyR) compared with patients that did not harbor a mutation in BCR-ABL, of whom 40% (n = 2/5) achieved an OHR and 50% (n = 2/4) achieved a MCyR (PMID 26040495)."
"['V299L', 'F317L', 'G250E']","[{'ncitCode': 'C60809', 'drugName': 'Bosutinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}",[],['26040495'],[],"Bosutinib is a dual SRC/ABL tyrosine kinase inhibitor (TKI) that is NCCN-listed and FDA-approved for adult patients with either newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) or CP, accelerated (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. In a phase I/II trial (NCT00261846) of bosutinib in 143 patients with Ph+ CML (AP, n = 79; BP, n=64) with resistance or intolerance to prior TKI therapy, 115 patients had mutation assessment at baseline (AP, n=62; BP, n=53), revealing mutations in F317L (AP, n = 4; BP, n = 4) and G250E (AP, n = 4; BP, n = 2) (PMID: 26040495). In the AP CML cohort, overall hematologic response (OHR) and major cytogenetic response rates (MCyR) were 62% (n = 16/26) and 44% (n = 11/25), respectively, in patients with at least one mutation (excluding T315I), versus 62% (n = 18/29) and 43% (n = 12/28) without a mutation (PMID: 26040495). In the BP CML cohort, OHR and MCyR rates were 35% (n = 6/17) and 20% (n = 3/15), respectively, in patients with at least one mutation (excluding T315I), versus 25% (n = 6/24) and 45% (n = 9/20) without a mutation (PMID: 26040495)."
"['V299L', 'F317L', 'F317I', 'F317C', 'T315A', 'F317V']","[{'ncitCode': 'C38713', 'drugName': 'Dasatinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['17496201', '20131302', '17339191']",[],"Dasatinib is a small molecule inhibitor of BCR-ABL and SRC family kinases that is FDA-approved for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy and is NCCN-listed. In a phase II, open-label, single-arm, multicenter clinical trial (#CA180015) of dasatinib in 36 patients with imatinib-resistant (n = 34 patients) or -intolerant (n = 2 patients) Ph+ ALL, major hematologic responses were achieved in 42% (15/36) of patients and complete cytogenetic responses were achieved by 58% (21/36) of patients (PMID:17496201). In a randomized, open-label, international, phase III study of dasatinib in 84 patients with Ph+ ALL resistant or intolerant to imatinib, the rates of confirmed major hematologic response in the once-(n = 40) and twice-daily (n = 44) dosing groups were 38% and 32%, respectively, and the rate of major cytogenetic response with once-daily dosing (70%) was higher than that with twice-daily dosing (52%) (PMID: 20131302). Compared with the twice-daily schedule, the once-daily schedule had shorter overall survival (median, 9.1 months versus 6.5 months, respectively) and longer progression-free survival (median, 3 months versus 4 months, respectively) (PMID: 20131302). In a study of nine Ph+ ALL patients who failed to respond to or relapsed during dasatinib therapy, BCR-ABL kinase sequences were analyzed before and during treatment and in all but one patient, resistance to dasatinib was found to be associated with mutations at residue 315 and/or at residue 317, including F317L (n = 3), F317I (n = 1), and T315A (n = 1) (PMID: 17339191)."
"['V299L', 'F317L', 'F317I', 'F317C', 'T315A', 'F317V']","[{'ncitCode': 'C38713', 'drugName': 'Dasatinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}",[],"['19589924', '17710227', '19779040']",[],"Dasatinib is a small molecule tyrosine kinase inhibitor (TKI) of BCR-ABL and SRC family kinases that is NCCN-listed and is FDA-approved for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. In a study looking at BCR-ABL mutation status in 71 imatinib-resistant patients with Ph+ leukemia before and during treatment with dasatinib as a second or third TKI, 31 patients relapsed on dasatinib with evidence of newly acquired resistance mutations, including F317L (n = 9/31), V299L (n = 4/31), T315A (n = 3/31), F317I (n = 2/31), F317C (n = 1/31), and F317V (n = 1/31), and one patient had evidence of multiple mutations (F317I + F317V + F317C) (PMID: 19589924). In a meta-analysis of three separate dasatinib trials in chronic phase CML, of 402 patients with a BCR-ABL mutation, patients with the F317L mutation had a high rate of complete hematologic response (13/14, 93%), but low rates of major (2/14, 14%) and complete (1/14, 7%) cytogenetic responses (PMID: 19779040). In a study of seventeen patients with Ph+ CML who developed resistance to dasatinib following imatinib, all patients had new BCR-ABL mutations at the time of relapse on dasatinib that were not detected at the time of relapse on imatinib, including V299L (n = 4/17), T315A ( n = 1/17), F317L (n = 1/17), and F317I (n = 1/17) (PMID: 17710227)."
"['V299L', 'Y253H', 'F359C', 'F317I', 'F317C', 'F359I', 'T315A', 'F317V', 'E255K', 'E255V', 'F317L', 'F359V', 'G250E']","[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['17405907', '11861307', '17189410']",[],"Imatinib is a tyrosine kinase inhibitor of BCR-ABL that is NCCN-listed and FDA-approved for adult patients with relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL). In a study of 297 evaluable Ph+ leukemia patients with evidence of hematologic or cytogenetic resistance to imatinib, amino acid substitutions at seven residues in the ABL kinase domain (KD) including E255K/V (n=21, 17%), Y253F/H (n=17, 13%), F359V/I (n=14, 11%), and G250E (n=13, 10%), accounted for the majority of all resistance-associated mutations (PMID: 17189410). In a retrospective study of 26 evaluable newly diagnosed elderly patients with Ph+ ALL who enrolled in the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) trial ADE10, BCR-ABL KD mutations were found in 21/26 patients (84%), including G250E (n = 5/21), Y253H (n = 2/21), E255K/V (n = 4/21), and F317L (n = 1/21) (PMID: 17405907). Upon sequencing the bone marrow of nine patients with Ph+ ALL who were treated with STI571 (imatinib) and developed resistance, 6/9 patients harbored the E255K mutation, which is located within the motif important for forming the pocket of the ATP-binding site in ABL (PMID: 11861307)."
"['V299L', 'Y253H', 'F359C', 'F317I', 'F317C', 'F359I', 'T315A', 'F317V', 'E255K', 'E255V', 'F317L', 'F359V', 'G250E']","[{'ncitCode': 'C62035', 'drugName': 'Imatinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}",[],"['19925053', '12623848', '17189410', '17785585', '20010464']",[],"Imatinib is a tyrosine kinase inhibitor of BCR-ABL that is NCCN-listed and FDA-approved for newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in the chronic phase. In a study of 297 evaluable Ph+ leukemia patients with evidence of hematologic or cytogenetic resistance to imatinib, amino acid substitutions at seven residues in the BCR-ABL kinase domain (KD) including E255K/V (n=21, 17%), Y253F/H (n=17, 13%), F359V/I (n=14, 11%), and G250E (n=13, 10%), accounted for the majority of resistance-associated mutations (PMID: 17189410). In a study (MAPTEST) of 92 Polish patients with Ph+ CML who were treated with imatinib for more than three months, twelve mutations were detected in 11/92 patients, including E255K (n = 1/11), E255V (n = 1/11), F359V (n = 2/11) and double-mutant F359V + Y253F (n = 1//11) (PMID: 20010464). In a study of 76 patients with Ph+ CML with suspected clinical resistance to imatinib, BCR-ABL kinase domain mutations were identified in 25/76 (33%) patients, including E255K (12%), G250E and Y253H (8% each), as well as F317L (4%) (PMID: 19925053). In a study analyzing BCR-ABL KD mutation status in 112 patients with persistent Ph+ CML who received a second-generation TKI after imatinib failure, several mutations were detected after imatinib and before second-line treatment, including G250E (n= 12), Y253H (n = 3), E255K (n = 3), F317L (n = 7), F359C (n = 3), and F359V (n = 1) (PMID: 17785585). Direct sequencing of 144 patients with Ph+ CML treated with imatinib for BCR-ABL KD mutations revealed multiple alterations that led to imatinib resistance, including G250E (n = 2), E255K (n = 5), E255V (n = 1), F317L (n = 2), and F359V (n = 2) (PMID: 12623848)."
"['V299L', 'F317L', 'F317I', 'F317C', 'T315A', 'F317V']","[{'ncitCode': 'C48375', 'drugName': 'Nilotinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 95, 'code': 'BLL', 'color': 'LimeGreen', 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'mainType': {'id': None, 'name': 'B-Lymphoblastic Leukemia/Lymphoma', 'tumorForm': 'LIQUID'}, 'tissue': 'Lymphoid', 'children': {}, 'parent': 'LNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],"['19075254', '15930265']",[],"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy and is NCCN-listed for adult patients with Ph+ acute lymphoblastic leukemia (ALL). In tritiated thymidine incorporation assays performed in Ba/F3 cells expressing one of eighteen different BCR-ABL mutations compared to BCR-ABL wildtype, 5/18 mutants were considered sensitive to nilotinib including V299L and 13/18 mutations were considered moderately to highly resistant to nilotinib, including F317L (PMID: 19075254). In cell proliferation assays, nilotinib was more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wildtype BCR-ABL or BCR-ABL mutants, including F317L, and biochemical assays showed that nilotinib inhibited ABL-catalyzed peptide substrate phosphorylation with approximately 20-fold higher potency than imatinib (PMID: 15930265)."
"['V299L', 'F317L', 'F317I', 'F317C', 'T315A', 'F317V']","[{'ncitCode': 'C48375', 'drugName': 'Nilotinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 560, 'code': 'CML', 'color': 'LightSalmon', 'name': 'Chronic Myelogenous Leukemia', 'mainType': {'id': None, 'name': 'Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MPN', 'level': 4, 'tumorForm': 'LIQUID'}",[],"['23086624', '19075254', '15930265']",[],"Nilotinib is a second-generation small molecule inhibitor of the BCR-ABL kinase that is NCCN-listed for adult patients with Ph+ CML and is FDA-approved for adult and pediatric patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (CP Ph+ CML) that is either newly diagnosed, resistant to, or intolerant to prior tyrosine kinase inhibitor therapy. In tritiated thymidine incorporation assays performed in Ba/F3 cells expressing one of eighteen different BCR-ABL mutations compared to BCR-ABL wildtype, 5/18 mutants were considered sensitive to nilotinib, including V299L, and 13/18 mutations were considered moderately to highly resistant to nilotinib, including F317L (PMID: 19075254). In cell proliferation assays, nilotinib was more effective than imatinib at inhibiting the proliferation of Ba/F3 cells expressing wildtype BCR-ABL or BCR-ABL mutants, including F317L, and biochemical assays showed that nilotinib inhibited ABL-catalyzed peptide substrate phosphorylation with âˆ¼20-fold higher potency than imatinib (PMID: 15930265). In a study of fifteen patients with TKI-resistant CML harboring the V299L mutation, 1/4 patients that received salvage therapy with nilotinib achieved a sustained major molecular response of 40+ months and another patient achieved a peripheral hematologic response for greater than six months (PMID 23086624)."
